A Covid-19 vaccine candidate developed by the University of Oxford and licensed to AstraZeneca has advanced into a Phase III clinical trial in the US.

The trial is designed to evaluate the safety, efficacy and immunogenicity of the AZD1222 vaccine to prevent Covid-19 in up to 30,000 adults aged 18 years and above.

Led by AstraZeneca, the study is funded by the US’ Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).

The COVID-19 Prevention Network (CoVPN), support by NIAID, will be part of the trial.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine.

“Should clinical trials demonstrate the vaccine protects against Covid-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US trial will involve healthy participants from different racial, ethnic and geographic groups, as well as those with stable underlying medical conditions, including HIV, who are at increased risk of Covid-19 infection.

Based on estimated transmission rates of the virus, sites outside the US are included, with centres in Peru and Chile set to begin enrolment soon.

Participants will be given two doses of AZD1222 or a saline control four weeks apart. Twice as many subjects will receive the vaccine candidate compared to saline control.

The study will analyse efficacy and safety in all participants, while local and systemic reactions and immune responses will be evaluated in 3,000 subjects.

Late-stage trials of the vaccine candidate are ongoing in the UK, Brazil and South Africa, with studies planned to launch in Japan and Russia. These trials, along with the US Phase III trial, will recruit up to 50,000 participants worldwide.

Results from the late-stage studies are expected to be available later this year.

Last month, AstraZeneca started dosing participants in a Phase I trial of monoclonal antibody (mAb) combination therapeutic AZD7442 to prevent and treat Covid-19.